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ABSTRACT
Pretreatment with D-myo-inositol-1,4,5-trisphosphate hexaso-
dium (D-myo-IP3), the sodium salt of the second messenger
inositol 1,4,5-trisphosphate (IP3), is cardioprotective and trig-
gers a reduction of infarct size comparable in magnitude to that
obtained with ischemic preconditioning. However, this obser-
vation is enigmatic; whereas IP3 signaling is conventionally
initiated by receptor binding, IP3 receptors are typically consid-
ered to be intracellular, and D-myo-IP3 is membrane-imperme-
able. We propose that this paradox is explained by the pres-
ence of poorly characterized external IP3 receptors and
hypothesize that: 1) infarct size reduction with D-myo-IP3 is
receptor-mediated; and 2) communication via gap junctions
and/or hemichannels is required to initiate this protection. To
investigate the role of receptor binding, isolated buffer-per-
fused rabbit hearts underwent 30 min of coronary occlusion
(CO) and 2 h of reflow. Prior to CO, hearts received no treat-
ment (controls), D-myo-IP3, L-myo-IP3 (enantiomer not recog-
nized by the IP3 receptor), D-myo-IP3  the IP3 receptor inhib-
itor xestospongin C (XeC), or XeC alone. Infarct size, assessed
by tetrazolium staining, was reduced with D-myo-IP3 treatment,
whereas hearts that received L-myo-IP3 or D-myo-IP3  XeC
showed no protection. To evaluate the contribution of gap
junctions/hemichannels, additional control and D-myo-IP3-
treated cohorts received a 5-min infusion of heptanol or Gap
27, two structurally distinct gap junction inhibitors, adminis-
tered at doses confirmed to attenuate intercellular transmission
of a gap junction-permeable fluorescent dye. There was no
infarct-sparing effect of D-myo-IP3 in inhibitor-treated hearts.
These data support the concepts that infarct size reduction
with D-myo-IP3 is triggered by receptor binding and that com-
munication via gap junctions/hemichannels is involved in initi-
ating this protection.
Inositol 1,4,5-trisphosphate (IP3) is a ubiquitous second
messenger generated in parallel with diacylglycerol in re-
sponse to activation of G-protein-coupled receptors. Previous
studies from our group have shown that prophylactic admin-
istration of D-myo-IP3 hexasodium, the sodium salt of IP3,
renders the heart resistant to a subsequent sustained isch-
emic insult and triggers a reduction of infarct size that is
comparable in magnitude to the cardioprotection achieved
with ischemic preconditioning (Gysembergh et al., 1999).
However, this observation is enigmatic; i.e., whereas IP3 (and
presumably D-myo-IP3) signaling is conventionally initiated
by receptor binding, IP3 receptors have historically been con-
sidered to be intracellular (specifically located on the endo-
plasmic reticulum or in the perinuclear region), and D-myo-
IP3 is well known to be membrane-impermeable (Berridge,
1993, 2002; Taylor and Broad, 1998; Wilcox et al., 1998;
Gysembergh et al., 1999; Ibarra et al., 2004; Vermassen et
al., 2004).
One potential explanation for this apparent paradox is that
reduction of infarct size triggered by exogenous D-myo-IP3 is
a nonspecific effect that occurs independently of IP3 receptor
binding. In this regard, there is one report of an apparent
increase in the fluidity of in vitro liposomal membrane prep-
arations with D-myo-IP3 (Brailoiu et al., 1998), the physio-
logic relevance and mechanisms of which are unknown. How-
ever, we propose that D-myo-IP3-induced cardioprotection is
receptor-mediated and, in particular, may be explained by
the existence of as-yet poorly characterized external IP3 re-
ceptors identified in proximity to cardiac gap junctions and at
the cell periphery (Kijima et al., 1993; Mackenzie et al., 2002;
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Vermassen et al., 2004). Accordingly, our aims in the current
study were to test the hypotheses that: 1) infarct size reduc-
tion initiated by prophylactic administration of exogenous
D-myo-IP3 is receptor-mediated; and 2) communication via
gap junctions or hemichannels may play a role in triggering
D-myo-IP3-induced cardioprotection.
Materials and Methods
This study was approved by the Institutional Animal Care and
Use Committee of the University of Massachusetts Medical School
and was performed in accordance with the Guide for the Care and
Use of Laboratory Animals from the Institute of Laboratory Animals
Resources (National Institutes of Health Publication, Vol. 25/28,
revised 1996).
Surgical Preparation
Experiments were conducted using the isolated buffer-perfused
rabbit heart model, a well characterized preparation utilized rou-
tinely by our group and others (Ytrehus et al., 1994; Bauer et al.,
1999; Gysembergh et al., 1999, 2001; Krieg et al., 2004). In brief, 84
New Zealand White rabbits weighing 2.5 to 3.5 kg were anesthetized
with an intramuscular injection of ketamine  xylazine (150 and 100
mg, respectively). A tracheostomy was performed, the animals were
ventilated with room air, the hearts were exposed via a left lateral
thoracotomy, and the pericardium was incised. For all animals en-
rolled in protocols 1 and 2, a dominant anterior branch of the left
circumflex coronary artery was ensnared with a 2-0 silk suture for
later occlusion/reperfusion.
The hearts were then excised and placed in an ice bath, and after
rapid cannulation of the aortic root, retrograde perfusion (nonrecir-
culating) was initiated at a pressure of 85 mm Hg. The buffer was
composed of 118 mM NaCl, 4.7 mM KCl, 24 mM NaHCO3, 1.2 mM
KH2PO4, 1.2 mM MgSO4-7H2O, 11 mM glucose, and 2.5 mM CaCl2
anhydrous in distilled water at a pH of 7.4 and was continuously
oxygenated with 95% O2, 5% CO2. The perfusate was warmed to
37°C, and heart temperature was maintained at 37°C by immersion
in a water-jacketed chamber. An incision was made in the left
atrium, and a latex balloon connected to a pressure transducer was
positioned in the left ventricular (LV) cavity for continuous assess-
ment of hemodynamic function. The balloon was initially inflated to
an end-diastolic pressure of 5 to 10 mm Hg, and thereafter, the
balloon volume was held constant. All hearts were paced at 210
beats/min via electrodes positioned on the right ventricle. After a
15-min equilibration period, baseline hemodynamic data (described
below) were obtained and baseline coronary flow was measured by
the timed collection of coronary effluent.
Protocol 1: Role of IP3 Receptors in D-myo-IP3-Induced
Cardioprotection
Study Design. If infarct size reduction seen with exogenous ad-
ministration of D-myo-IP3 is receptor-mediated, we first reasoned
that L-myo-IP3, a negative enantiomer of D-myo-IP3 not recognized
by the IP3 receptor (Polokoff et al., 1988), would fail to evoke cardio-
protection. To test this concept, hearts enrolled in protocol 1 (n  28)
underwent 30 min of coronary artery occlusion (CO) followed by 2 h
of reperfusion, achieved by tightening and releasing the coronary
snare (Fig. 1). The sustained test occlusion was preceded by an
intervention period, during which hearts were randomly assigned to
receive 6 M D-myo-IP3 [final concentration in perfusate (Gysem-
bergh et al., 1999)], 6 M L-myo-IP3, brief preconditioning (PC)
ischemia, or uninterrupted buffer perfusion (controls) (n  6–8/
group). Both D-myo-IP3 and L-myo-IP3 (Calbiochem, San Diego, CA)
were dissolved in 5 ml of buffer and administered over 1 min, begin-
ning 25 min before the onset of coronary artery occlusion, via a side
arm located immediately proximal to the heart. A 6 M concentra-
tion of D-myo-IP3 given in this manner was shown in initial pilot
studies to provide optimum cardioprotection. The lowest doses that
evoked protection were on the order of 0.1 to 0.5 M, whereas,
interestingly, higher concentrations of D-myo-IP3 (i.e., 20 M) failed
to limit infarct size and may even have modestly exacerbated necro-
sis (data not shown). The preconditioned group was included, be-
cause this represents the current “gold standard” of experimental
cardioprotection, and was initiated by the standard stimulus of a
5-min brief coronary artery occlusion followed by 10 min of reflow
(Fig. 1).
As a second test of this hypothesis, we further proposed that if
D-myo-IP3-induced cardioprotection is receptor-mediated, then coad-
ministration of an IP3 receptor inhibitor should attenuate the bene-
fits of D-myo-IP3 treatment. Accordingly, additional post hoc cohorts
of control (n  3) and D-myo-IP3-treated hearts (n  6) received the
IP3 receptor antagonist xestospongin C (XeC) (Miyamoto et al., 2000;
Ibarra et al., 2004). XeC (Calbiochem) was dissolved in DMSO,
diluted in 10-ml buffer, and infused via a second proximal side arm
for a total of 10 min, beginning 9 min before D-myo-IP3 treatment
(final concentration of XeC in perfusate, 3 M; final concentration of
DMSO in perfusate, 0.01%) (Fig. 1). Our choice of the 3 M dose of
XeC was based on previous studies investigating IP3-mediated sig-
naling in guinea pig papillary muscle (Miyamoto et al., 2000). Infu-
sion of XeC was terminated immediately after D-myo-IP3 treatment
(thereby allowing a lengthy 24-min period without XeC treatment
before the onset of coronary occlusion) in an effort to limit the action
of the inhibitor to the “trigger phase” of D-myo-IP3-induced cardio-
protection, rather than influencing the sustained ischemic period
per se.
For all hearts, hemodynamics (i.e., maximum LV systolic pres-
Fig. 1. Study design for protocols 1 and 2.
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sure, end-diastolic pressure, and peak-positive and peak-negative
LV dP/dt) were recorded at 1-min intervals throughout the protocol
on a computerized data acquisition system (Micro-Med, Louisville,
KY), and coronary flow was measured by timed collection of effluent
at 10 min into coronary occlusion and at 10 min and 2 h postreflow.
At the conclusion of the 2-h reperfusion period, the coronary
branch was briefly reoccluded and fluorescent polymer beads (2–9
m: Duke Scientific, Palo Alto, CA) were injected into the coronary
circulation to delineate the extent of the occluded vascular bed or
area at risk of infarction (AR). The heart was immediately removed
from the apparatus, sliced into five to seven transverse sections,
illuminated under ultraviolet light, and digitally photographed. To
distinguish necrotic from viable myocardium, the heart sections were
then incubated in triphenyltetrazolium chloride for 15 min at 37°C,
rephotographed, and stored in formalin (Vivaldi et al., 1985; Ytrehus
et al., 1994; Bauer et al., 1999; Gysembergh et al., 1999, 2001).
Endpoints. The primary endpoint of protocol 1 was infarct size.
For all hearts, right ventricular tissue was trimmed and each LV
heart slice was weighed. AR and area of necrosis (AN) in each heart
slice were quantified from the digital photographs using image anal-
ysis software (SigmaScan Pro; Systat, Point Richmond, CA), cor-
rected for tissue weight, and summed for each heart. AR was then
expressed as a percentage of the total LV weight, and AN was
expressed as a percentage of the AR (Ytrehus et al., 1994; Bauer et
al., 1999; Gysembergh et al., 1999, 2001).
Secondary endpoints of the study were hemodynamics and coro-
nary flow. LV pressures and LV dP/dt were tabulated for each heart
at baseline (before randomization), immediately before CO, at 5 and
30 min into CO, and at 15 min, 30 min, 1 h, and 2 h following relief
of ischemia. For each time point, LV-developed pressure was calcu-
lated as the difference between maximum LV systolic pressure and
end-diastolic pressure.
Protocol 2: Effect of Gap Junction Blockers on D-myo-IP3-
Induced Cardioprotection
The goal of protocol 2 was to investigate the possible contribution
of gap junctions to the reduction of infarct size initiated by D-myo-
IP3. Accordingly, three additional pairs of control and D-myo-IP3-
treated hearts (n  38) were pretreated with heptanol (Sigma-Al-
drich, St. Louis, MO), Gap 27 (Tocris Cookson Inc., Ellisville, MO), or
no inhibitor (buffer alone) (n  6–7/group). Heptanol is a classic and
reversible, albeit nonselective, gap junction inhibitor (Evans and
Boitano, 2001), whereas Gap 27 is a novel peptide homolog to extra-
cellular loop of connexin 43, the primary cardiac gap junction protein
(Chaytor et al., 1997; Boitano and Evans, 2000; Evans and Boitano,
2001). The inhibitors were infused over 5 min via a proximal side
port beginning 4 min before D-myo-IP3 treatment with final concen-
trations of heptanol and Gap 27 in the perfusate of 0.5 mM and 6 M,
respectively. Doses of heptanol in the range from 0.5 to 2 mM have
been used previously in isolated buffer-perfused heart models to
assess the role of gap junction-mediated communication in the set-
ting of ischemia-reperfusion (Garcia-Dorado et al., 1997; Gysem-
bergh et al., 2001; Li et al., 2002; Saltman et al., 2002; Miura et al.,
2004) with concentrations 1 mM considered relatively selective for
gap junction uncoupling (Christ et al., 1999; Gysembergh et al.,
2001). In contrast, Gap 27, although selective for connexin 43, has
not, to our knowledge, been administered to the intact heart; thus,
we made an empiric choice in the low micromolar range and vali-
dated its efficacy in protocol 3. As described for the use of XeC in
protocol 1, infusions of both heptanol and Gap 27 were terminated
immediately upon administration of D-myo-IP3 in an effort to have
the agents present only during the trigger phase of D-myo-IP3-in-
duced cardioprotection.
All of the hearts underwent 30 min of sustained coronary artery
occlusion and 2 h of reperfusion (Fig. 1). Hemodynamics and coro-
nary flow were assessed repeatedly throughout the protocol, and
infarct size, the primary endpoint, was quantified as described for
protocol 1.
Protocol 3: Confirmation of Gap Junction Inhibition
To confirm that the concentrations of 0.5 mM heptanol and, im-
portantly, 6 M Gap 27 administered in protocol 2 inhibited gap
junctions/hemichannels in normoxic myocardium (i.e., the conditions
under which D-myo-IP3 was administered and initiated protection),
we assessed the intercellular transfer and tissue penetration of Lu-
cifer yellow, a gap junction-permeable (but membrane-impermeable)
fluorescent tracer dye (Ruiz-Meana et al., 2001; Miura et al., 2004),
in nine additional hearts. After stabilization, hearts received a 5-min
infusion of heptanol or Gap 27 as described for protocol 2 or buffer
alone (n  3/group). The hearts were then rapidly removed from the
apparatus and cut into five transverse slices. We used previously
published methods (Ruiz-Meana et al., 2001; Miura et al., 2004) with
minor modifications to introduce the dye into the myocardial slices
and quantify fluorescence. Specifically, in the three slices obtained
from the mid-myocardial region (apex and base discarded), shallow
incisions were made on the epicardial surface at a uniform calibrated
depth of 1 mm, thereby disrupting sarcolemmal membranes and
allowing initial uptake of the membrane-impermeable dye. The
slices were then incubated for 20 min in oxygenated buffer contain-
ing 2.5 ml/min Lucifer yellow (Sigma-Aldrich). Transmural cuts were
made at the sites of the shallow incisions, and the cut surfaces (three
per heart) were photographed under ultraviolet light. To ensure that
samples from different treatment groups were imaged under the
same conditions, one control, one heptanol-, and one Gap 27-treated
sample were included in each photograph. Digital images of the cut
surface were planimetered, and average intensity of fluorescence
within each cut surface was quantified (SigmaScan Pro).
Statistical Analyses
For protocols 1 and 2, AN/AR and AR/LV were compared among
groups by analysis of variance (ANOVA), whereas for variables mea-
sured repeatedly throughout the protocols (hemodynamics, coronary
flow), two-factor ANOVA (for group and time) was applied. If signif-
icant F values were obtained, post hoc pairwise comparisons were
made using the Newman-Keuls test. Comparisons of hemodynamics
and coronary flow were made using both absolute and relative (nor-
malized to baseline) values; however, because both analyses yielded
identical results, all data are reported for simplicity as percentage of
baseline. Data obtained in protocol 3 (intensity of Lucifer yellow
fluorescence for control, heptanol-, and Gap 27-treated hearts) were
compared by ANOVA  the Newman-Keuls post test. All of the
values are reported as the means  S.E.M., and p values 0.05 were
considered statistically significant.
Results
Protocol 1: Role of IP3 Receptors in D-myo-IP3-Induced
Cardioprotection
Hemodynamics. Baseline values of LV-developed pres-
sure and coronary flow averaged 92 mm Hg and 76 ml/min
with no significant differences among the six groups.
Administration of D-myo-IP3, L-myo-IP3, or XeC had no
effect on hemodynamics with LV-developed pressure main-
tained at 97 to 99% of baseline values. However, as expected,
hearts that received brief PC ischemia were modestly
stunned before the onset of sustained coronary artery occlu-
sion (i.e., developed pressure reduced to 79  3% of baseline
values; p  0.05 versus baseline and p  0.05 versus con-
trols). LV-developed pressure was reduced in all hearts dur-
ing coronary occlusion and remained depressed with no dif-
ferences among the six cohorts throughout reperfusion
(Table 1). These data support the concept that precondition-
ing has no independent beneficial effect on the acute recovery
of viable myocardium salvaged by reperfusion (Colantonio et
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al., 2004) and suggest that, similarly, D-myo-IP3 does not
attenuate postischemic contractile dysfunction. Results ob-
tained for peak-positive and peak-negative LV dP/dt were
similar to those observed for LV-developed pressure (data not
shown).
Infarct Size. The area at risk was 41  3, 49  4, 36  3,
36  1, 42  2, and 42  3% of the total LV weight in the
control, PC, D-myo-IP3-treated, L-myo-IP3-treated, XeC-
treated, and XeC  D-myo-IP3-treated groups, respectively,
and although by chance AR/LV tended to be larger in hearts
that received PC ischemia (p  0.09), this difference was not
significant.
In control hearts, the area of necrosis averaged 52  6% of
the risk region (Fig. 2). Infarct size was reduced with both PC
ischemia and D-myo-IP3 treatment to a mean of 29 and 31%,
respectively (p  0.05 versus controls). In contrast, the neg-
ative enantiomer, L-myo-IP3, failed to trigger cardioprotec-
tion (mean AN/AR of 58%; p  N.S. versus controls), and
coadministration of XeC  D-myo-IP3 blocked the benefits of
D-myo-IP3 treatment (mean AN/AR of 49%; p  0.05 versus
D-myo-IP3 and p  N.S. versus controls) (Fig. 2).
Protocol 2: Effect of Gap Junction Blockers on D-myo-IP3-
Induced Cardioprotection
Hemodynamics. Mean baseline values of LV-developed
pressure and coronary flow were 88 mm Hg and 74 ml/min
with no differences among groups. As expected, LV-devel-
oped pressures tended to be reduced in all hearts following
administration of the gap junction blockers (Gysembergh et
al., 2001; Li et al., 2002; Miura et al., 2004), averaging 75 to
87% of baseline values immediately before the onset of coro-
nary occlusion. However, there were no significant differ-
ences among groups in either LV-developed pressure or cor-
onary flow throughout the protocol (Table 2).
Infarct Size. AR/LV ranged from 33 to 41% and did not
differ among the six treatment groups. Infarct size in
control and D-myo-IP3-treated cohorts in protocol 2 aver-
aged 54 and 30% of the risk region, comparable to the
values of 52 and 31% observed in protocol 1. Administra-
tion of heptanol had no effect on the development of necro-
sis in control hearts but blocked the reduction of infarct
size achieved with D-myo-IP3; i.e., mean AN/AR was 55% in
the heptanol  D-myo-IP3-treated group (p  N.S. versus
heptanol-treated controls; Fig. 3). Infarct size in gap-
treated controls was 39% of the risk region, a value that
interestingly tended to be smaller than that seen in the
no-inhibitor controls. Nonetheless, there was no evidence
of D-myo-IP3-induced cardioprotection in the presence of
Gap 27 (mean AN/AR of 44%; p  N.S. versus gap-treated
controls; Fig. 3).
Protocol 3: Confirmation of Gap Junction Inhibition
Mean intensity of fluorescence; i.e., the index of gap junc-
tion-mediated transfer and penetration of Lucifer yellow into
the myocardial samples, was significantly reduced in hearts
treated with heptanol and Gap 27 versus buffer-treated con-
trols (156  21* and 121  11* versus 216  9 units, respec-
tively; , p  0.05 versus controls; Fig. 4).
Discussion
In the current study, we provide data in support of the
hypotheses that 1) reduction of infarct size triggered by pro-
phylactic administration of D-myo-IP3 is receptor-mediated
and 2) communication via gap junctions/hemichannels plays
a role in initiating D-myo-IP3-induced cardioprotection. To
our knowledge, these findings constitute the first insight into
TABLE 1
Hemodynamics: Protocol 1
Values are reported as percentage of baseline (100%).
PreCO
Occlusion Reperfusion
10 min 30 min 10 min 15 min 1 h 2 h
LV-Developed Pressure*
Control 98  1 26  3 57  6 55  5 41  8
PC 79  3† 22  4 47  6 49  9 37  10
D-myo-IP3 97  3 37  9 56  7 50  4 44  4
L-myo-IP3 99  5 31  7 53  10 50  9 45  9
XeC  Control 98  3 34  6 62  10 52  11 47  10
XeC  D-myo-IP3 97  2 29  4 50  5 44  6 40  6
Coronary Flow‡
Control 48  5 86  6 54  14
PC 56  5 73  10 54  15
D-myo-IP3 55  5 76  5 55  9
L-myo-IP3 58  4 71  5 57  5
XeC  Control 57  8 82  8 57  8
XeC  D-myo-IP3 53  2 81  4 63  9
* p 0.01 over time.
† p  0.05 vs. control.
‡ p  0.01 over time; no significant differences among groups.
Fig. 2. Area of necrosis expressed as a percentage of the risk region for
protocol 1. , p  0.05 versus control.
D-myo-IP3, Gap Junctions, and Cardioprotection 1389
the mechanisms by which pretreatment with D-myo-IP3 ren-
ders the rabbit heart resistant to subsequent infarction.
Infarct Size Reduction with D-myo-IP3. IP3 is a ubiq-
uitous second messenger generated in parallel with diacyl-
glycerol via activation of G-protein-coupled receptors and
subsequent phospholipase C-mediated hydrolysis of phos-
phatidylinositol 4,5-bisphosphate. The established classical
role of IP3 lies in the control of calcium homeostasis (specif-
ically mobilizing the release of calcium from intracellular
stores) initiated by the binding of IP3 to IP3 receptors (Ber-
ridge, 1993, 2002; Vermassen et al., 2004). Moreover, data
from our group and others suggest that alterations in calcium
homeostasis (and endogenous IP3 signaling, in particular)
may contribute to cardioprotection initiated by both brief
preconditioning ischemia and opioid receptor stimulation
(Node et al., 1997; Przyklenk et al., 1997, 1999; Bauer et al.,
1999; Gysembergh et al., 1999; Barrere-Lemaire et al., 2005).
We further found that pretreatment of isolated buffer-
perfused rabbit hearts with exogenous D-myo-IP3 was cardio-
protective. That is, the analog delivered as a slow bolus 25
min before the onset of coronary artery occlusion triggered a
35% reduction of infarct size that was comparable in magni-
tude to that obtained with brief preconditioning ischemia
(Gysembergh et al., 1999), an observation corroborated by
the 40% reduction of infarct size seen with D-myo-IP3 in
protocols 1 and 2. However, this finding is intriguing given
that D-myo-IP3 is well recognized to be membrane-imperme-
able and that IP3 receptors are historically considered to be
intracellular (Wilcox et al., 1998; Gysembergh et al., 1999).
To gain insight into this apparent paradox, we first ex-
ploited the stereospecific requirements of IP3 receptor
stimulation and reasoned that, if infarct size reduction with
D-myo-IP3 is receptor-mediated, then time- and concentra-
tion-matched pretreatment with the negative enantiomer,
L-myo-IP3, should fail to elicit protection. Results obtained in
protocol 1 demonstrated that, whereas D-myo-IP3 limited in-
farct size, the extent of necrosis was indeed comparable in
L-myo-IP3-treated hearts versus controls. Although we can-
not definitively exclude the possibility that, as in the in vitro
liposomal preparation (Brailoiu et al., 1998), the benefits of
D-myo-IP3 may involve nonspecific actions such as alter-
ations in membrane fluidity, these data are consistent with
the concept that D-myo-IP3-induced cardioprotection is recep-
tor-mediated.
Fig. 4. Penetration of the gap junction-permeable fluorescent dye Lucifer
yellow in samples from control (buffer-treated) and heptanol- and Gap
27-treated hearts. Top, mean intensity of fluorescence. , p  0.05 versus
control. Bottom, original photographs of samples from the three treat-
ment groups. Arrows denote the sites of the calibrated incisions (1-mm
depth) made on the epicardial (Epi) surface. Endo, endocardial surface.
TABLE 2
Hemodynamics: Protocol 2
Values are reported as percentage of baseline (100%).
PreCO
Occlusion Reperfusion
10 min 30 min 10 min 15 min 1 h 2 h
LV-Developed Pressure*
Control 99  4 28  6 68  8 62  8 50  8
D-myo-IP3 97  2 33  4 59  4 53  4 43  4
Heptanol  Control 79  12 42  7 55  10 45  7 37  6
Heptanol  D-myo-IP3 75  14 31  4 51  11 44  9 44  6
Gap 27  Control 87  2 36  5 75  6 62  10 58  11
Gap 27  D-myo-IP3 83  6 43  6 59  7 49  4 49  6
Coronary Flow†
Control 54  4 79  5 63  6
D-myo-IP3 59  3 79  4 60  4
Heptanol  Control 59  4 76  6 43  4
Heptanol  D-myo-IP3 51  6 82  11 53  6
Gap 27  Control 59  3 91  7 67  4
Gap 27  D-myo-IP3 68  11 78  8 68  7
* p  0.01 over time; P  0.08 (not significant) among groups.
† p  0.01 over time; no significant differences among groups.
Fig. 3. Area of necrosis expressed as a percentage of the risk region for
protocol 2. , p  0.05 versus matched no-inhibitor control; †, p  N.S.
versus matched inhibitor-treated control.
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If IP3 receptor activation is involved, then coadministra-
tion of an IP3 receptor inhibitor together with D-myo-IP3
should negate the protective effects of the analog. However,
this antagonist approach is complicated by the small number
of available tool drugs targeting the IP3 receptor and, for the
agents of choice [XeC and 2-aminoethoxydiphenyl borate (2-
APB)], their limited use and poor characterization in intact
tissues and organs (Taylor and Broad, 1998; Wilcox et al.,
1998; Gysembergh et al., 1999). In fact, we found in previous
studies that the temporal profile of 2-APB (i.e., prolonged
1-h time to onset of action followed by sustained inhibition)
made it unsuitable for the selective blockade of a brief ante-
cedent protective stimulus in the isolated rabbit heart
(Gysembergh et al., 1999). Protocol 1 revealed that XeC
blocked the reduction of infarct size seen with D-myo-IP3 but
had no effect on the development of necrosis in control hearts.
Despite the caveats involved in the use of XeC [i.e., the agent
is membrane-permeable and thus does not discern the site of
IP3 receptor stimulation; both XeC and 2-APB may also block
store-operated calcium entry, inhibit sarco/endoplasmic re-
ticulum calcium ATPase activity, and, paradoxically, poten-
tiate release of calcium from intracellular stores, thus raising
questions regarding selectivity (Miyamoto et al., 2000; Boot-
man et al., 2002)], these data, together with the lack of
benefit of the negative enantiomer L-myo-IP3, support the
concept that D-myo-IP3-induced cardioprotection is receptor-
mediated.
Role of Gap Junctions and/or Hemichannels in
D-myo-IP3-Induced Cardioprotection. If infarct size re-
duction with D-myo-IP3 is initiated by receptor binding and if
intracellular receptors are most probably not involved, these
data imply the presence of additional populations of presum-
ably external IP3 receptors. Although it is well recognized
that IP3 receptors are expressed on the endoplasmic reticu-
lum, there is increasing evidence obtained from multiple cell
types for the presence of IP3 receptors on other organelles, in
close association with cytoskeletal and scaffolding proteins,
and, most notably, on the plasma membrane (Khan et al.,
1992; Feng and Kraus-Friedmann, 1993; Barrera et al., 2004;
Vermassen et al., 2004). Moreover, despite the paucity of
data obtained in cardiac cells, IP3 receptors have been iden-
tified in the subsarcolemmal region, at the cell periphery,
and at the intercalated disks (Kijima et al., 1993; Mackenzie
et al., 2002; Vermassen et al., 2004).
This latter observation, together with preliminary findings
from our laboratory implicating the possible presence of IP3
receptors at the periphery of rabbit cardiomyocytes,
prompted us to propose that the reduction of infarct size
achieved with exogenous D-myo-IP3 may be triggered by
binding to external IP3 receptors associated with cardiac gap
junctions or hemichannels and, most importantly, that com-
munication via connexin-formed channels may play a role in
D-myo-IP3-induced cardioprotection. In this regard, evidence
in support of a functional coupling between IP3 receptors and
gap junctions has been described in confluent monolayers of
rat kidney cells where 2-APB was shown to block intercellu-
lar gap junction-mediated communication (Harks et al.,
2003).
We tested this hypothesis by using two structurally dis-
tinct gap junction inhibitors, the classic but nonselective
agent heptanol, as well as the novel and selective connexin-
mimetic peptide, Gap 27, at concentrations confirmed by our
quantitative assessment of Lucifer yellow fluorescence to
inhibit intercellular gap junction-mediated communication
in normoxic rabbit heart. D-myo-IP3 failed to limit infarct size
when administered in the presence of either inhibitor; area of
necrosis was comparable in heptanol  D-myo-IP3 and Gap 
D-myo-IP3-treated groups versus matched inhibitor-treated
controls. This lack of D-myo-IP3-induced cardioprotection in
the presence of heptanol and Gap 27 is consistent with the
concept that communication via gap junctions is involved in
initiating the infarct-sparing effect of D-myo-IP3.
The goal of our study was to investigate the role of con-
nexin-formed channels in infarct size reduction triggered by
D-myo-IP3. However, gap junction-mediated intercellular
communication has also been proposed to contribute to lethal
myocardial ischemia-reperfusion injury per se, a concept
based in part on reports that heptanol at concentrations of 1
to 2 mM is cardioprotective (Garcia-Dorado et al., 1997; Salt-
man et al., 2002; Miura et al., 2004). These data are in
apparent contrast to previous results from our group
(Gysembergh et al., 2001; Li et al., 2002) and current results
obtained in protocol 2 in which heptanol (concentration of 0.5
mM infused for 5 min followed by 24 min of washout) had no
effect on infarct size in control hearts. In addition to varia-
tions in dose [and thus possibly the loss of selectivity at
concentrations 1 mM (Christ et al., 1999)], this discrepancy
may be due to differences in the timing of treatment. Hepta-
nol is known to rapidly and reversibly disrupt gap junction-
mediated communication. Thus, perhaps not surprisingly, in
all studies showing reduction of ischemia- or reperfusion-
induced injury with heptanol, the agent was administered
either during sustained ischemia (Miura et al., 2004), during
reoxygenation (Garcia-Dorado et al., 1997), or with only a
brief 5-min washout period (Saltman et al., 2002).
Interestingly, we did observe a trend toward smaller in-
farcts in gap-treated control hearts when compared with
no-inhibitor controls; in fact, there was no statistical differ-
ence in infarct size between Gap 27-controls and D-myo-IP3-
treated hearts. Although both heptanol and Gap 27 are re-
versible inhibitors of gap junction-mediated communication,
this seemingly disparate effect of Gap 27 versus heptanol
may reflect the reportedly more prolonged inhibition of cell-
cell communication with Gap 27 [i.e., 20–60 min (Chaytor
et al., 1997; Boitano and Evans, 2000; Evans and Boitano,
2001)], which in contrast to the effects of heptanol would
persist into the 30-min sustained ischemic insult. Although
further studies are required to establish the specific temporal
profile of Gap 27 in the intact heart, the tendency toward
smaller infarcts in gap-treated controls would be consistent
with the hypothesis that accelerated the closure of gap junc-
tions during sustained myocardial ischemia is cardioprotec-
tive (Miura et al., 2004). Moreover, the results of protocol 2
may be interpreted to suggest that Gap 27 does not block
infarct size reduction with D-myo-IP3 as such but, rather,
that D-myo-IP3 fails to confer greater protection in the pres-
ence of Gap 27. Additional experiments are required to dis-
cern between these two possibilities.
Future Directions. Results obtained in the current study
implicate the involvement of IP3 receptor stimulation and
intercellular communication via gap junctions as initial steps
in D-myo-IP3-induced cardioprotection. However, multiple
questions regarding the infarct-sparing effect of D-myo-IP3
remain unexplored. First, on a fundamental level, although
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D-myo-IP3 administered 25 min before the onset of sustained
occlusion limits infarct size, the precise temporal character-
istics of D-myo-IP3-induced cardioprotection are unknown.
Second, all of current data were obtained using IP3 analogs
and pharmacologic antagonists in the rabbit heart model,
and arguably, more definitive insight may be provided by
interrogating the effects of D-myo-IP3 in genetically modified
mice. However, this approach is undermined by the fact that
mice in which the IP3 receptor gene has been disrupted, as
well as connexin 43 null mice, die shortly after birth (Matsu-
moto and Nagata, 1999; Suadicani et al., 2000). Third, we
have focused on the trigger phase of infarct size reduction
with D-myo-IP3, and although pilot experiments suggest the
involvement of phosphatidylinositol 3-kinase signaling
(Przyklenk et al., 2004), the distal mediators and signaling
pathways activated by administration of the analog are
largely undefined. Finally, the identity of the IP3 receptor
isoform(s) involved in the infarct-sparing effect of D-myo-IP3
(Thrower et al., 2001) as well as details concerning the na-
ture of the inter-relationship between the relevant popula-
tion of IP3 receptors and connexin-formed channels await
further study.
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